Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
4 pending office actions • 2 art units • 4 examiners • 0 of 4 (0%) have an AI response strategy ready • 3 patents granted in the last 365 days
Voronoi Inc. is currently managing 4 pending office actions within the Biotechnology & Pharmaceuticals technology area. These actions are distributed among a matching number of distinct examiners, indicating that each pending matter is assigned to a different individual. The prosecution activity spans 2 distinct art units, suggesting that the company's technical focus is divided across different specialized groups within the patent office.
FERGUSON, JALISA HOLMES is identified as the busiest examiner for this portfolio, currently overseeing 1 pending office action. This figure matches the workload of the other distinct examiners involved in the portfolio. The presence of 4 pending office actions across 2 distinct art units reflects a distributed prosecution strategy where multiple examiners are reviewing the company's intellectual property simultaneously.
Practitioners should note that while the workload is spread across multiple examiners, the concentration in 2 distinct art units may lead to some consistency in examination themes. The current volume represents the total active administrative burden for the Voronoi Inc. portfolio in this technology sector.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §112 only | 1 (25%) |
| Multi-statute (no §101) | 3 (75%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| FERGUSON, JALISA HOLMES | 1 | 61.1% | +43.8% |
| HEITMEIER, KENDALL NICOLE | 1 | 65.9% | +41.0% |
| RODRIGUEZ-GARCIA, VALERIE | 1 | 68.9% | +31.8% |
| ABDALHAMEED, MANAHIL MIRGHANI ALI | 1 | 50.3% | +38.2% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 3 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18559542 | HETEROARYL DERIVATIVE, METHOD FOR PREPARING SAME, AND PHARMACEUTICAL COMPOSITION COMPRISING SAME AS ACTIVE INGREDIENT | ABDALHAMEED, MANAHIL MIRGHANI ALI | 17d overdue |
| 18705952 | QUINAZOLINE DERIVATIVE COMPOUND AND USE THEREOF | HEITMEIER, KENDALL NICOLE | — |
| 18692229 | HETEROARYL DERIVATIVE AND USE THEREOF | RODRIGUEZ-GARCIA, VALERIE | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 4 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18559542 | HETEROARYL DERIVATIVE, METHOD FOR PREPARING SAME, AND PHARMACEUTICAL COMPOSITION COMPRISING SAME AS ACTIVE INGREDIENT | ABDALHAMEED, MANAHIL MIRGHANI ALI | 17d overdue |
| 18887279 | HETEROARYL DERIVATIVE COMPOUNDS, AND USES THEREOF | FERGUSON, JALISA HOLMES | — |
| 18705952 | QUINAZOLINE DERIVATIVE COMPOUND AND USE THEREOF | HEITMEIER, KENDALL NICOLE | — |
| 18692229 | HETEROARYL DERIVATIVE AND USE THEREOF | RODRIGUEZ-GARCIA, VALERIE | — |
| Art Unit | Apps |
|---|---|
| 1621 | 2 |
| 1622 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18887279 | HETEROARYL DERIVATIVE COMPOUNDS, AND USES THEREOF | FERGUSON, JALISA HOLMES | — | §112 | Non-Final OA | — | Pending | Sep 17, 2024 |
| 18705952 | QUINAZOLINE DERIVATIVE COMPOUND AND USE THEREOF | HEITMEIER, KENDALL NICOLE | 1621 | §102§103§112 | Non-Final OA | — | Pending | Apr 29, 2024 |
| 18692229 | HETEROARYL DERIVATIVE AND USE THEREOF | RODRIGUEZ-GARCIA, VALERIE | 1621 | §103§112 | Non-Final OA | — | Pending | Mar 14, 2024 |
| 18559542 | HETEROARYL DERIVATIVE, METHOD FOR PREPARING SAME, AND PHARMACEUTICAL COMPOSITION COMPRISING SAME AS ACTIVE INGREDIENT | ABDALHAMEED, MANAHIL MIRGHANI ALI | 1622 | §102§112Other | Non-Final OA | 17d overdue | Pending | Nov 07, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial